Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 47Carcinoma, Hepatocellular 9Triple Negative Breast Neoplasms 7Stomach Neoplasms 6Inflammatory Breast Neoplasms 6Lymphoma, Large B-Cell, Diffuse 4Urinary Bladder Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Recurrence 2Lymphoma 2Breast Neoplasms, Male 2Breast Diseases 2Upper Tract Urothelial Carcinoma 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Pancreatic Neoplasms 1Oesophagogastric Cancer 1Neoplastic Cells, Circulating 1Neoplasms, Unknown Primary 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

eribulin 2tislelizumab 1camrelizumab 1anlotinib 1Vinorelbine 1Taxes 1Epirubicin 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HER2-negative Breast Cancer × Epirubicin × Clear all
NCT04498793 2020-09-03

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
55 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡